PDC*LINE PHARMA HAS BEEN SELECTED FOR AN ORAL PRESENTATION AT THE 37th EUROPEAN IMMUNOGENETICS AND HISTOCOMPATIBILITY (EFI) CONFERENCE!
We are delighted to announce that we have been selected for an oral presentation at the 37th European Immunogenetics and Histocompatibility (EFI) Conference!
The presentation has been made May 21th by Séverine Planel.
Title of the talk was: Humoral response in lung cancer patients treated with a plasmacytoid dendritic allogeneic cell line-based cancer vaccine.
Using an antibody-mediated complement-dependent cytotoxicity (CDC) assay in flow cytometry using healthy donor’s or patient’s sera, we have shown that PDC*line cells were resistant to the complement dependent killing mediated by patient’s anti-HLA Ab despite the functionality of the patient’s complement system. Interestingly, we have shown that PDC*line cells express high level of membrane-bound complement regulatory proteins (mCRPs: CD46, CD55, and CD59) render them resistant to Ab-mediated CDC as shown by experiments using blocking Ab. Altogether, these results show the innocuity and the absence of deleterious effect of anti-HLA Ab on PDC*line cells used as a cancer vaccine platform.
Abstract of the presentation is available through this link: /sites/default/files/images/ABSTRACT%20EFI%202024_vFinal.pdf
About the event:
The conference is the annual event of the European Federation of Immunogenetics (EFI). It has been held in Geneva, Switzerland from 20 - 23 May 2024.
